 |
 |
| Expected to close by the end of September, Alcon's acquisition of LumiThera will support further clinical trials of the US firm's multi-wavelength photobiomodulation (PBM) approach - called "Valeda" - to treating dry AMD. Image: LumiThera. |
| © 2025 SPIE Europe |
|
